Free Newsletter
Daiichi chief 'confident' in Ranbaxy's future
The head of Daiichi Sankyo, the Japanese pharmaceutical company, expressed his regrets over the high cost of the purchase last year of Ranbaxy, the Indian generic drugs group, while defending the future benefits of the deal. Report
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: